First Patients Dosed in Phase 1 Trial Testing ARV-471 in Advanced, ER-Positive Breast Cancer

First Patients Dosed in Phase 1 Trial Testing ARV-471 in Advanced, ER-Positive Breast Cancer
The first patients have been dosed in a Phase 1 trial evaluating Arvinas' experimental therapy ARV-471 for locally-advanced or metastatic ER-positive, HER2-negative breast cancer. Approximately 80% of newly-diagnosed breast cancers produce a protein called an estrogen receptor (ER). In these cancers, the hormone estrogen binds to its receptor, causing the cells to grow and multiply. Therefore, anti-estrogen therapies — such as tamoxifen and fulvestrant (brand name Faslodex by AstraZeneca) — that reduce estrogen production or block the ER are standard-of-care for this type of cancer. However, many patients become resistant to these therapies, which results in advanced cancers that are more difficult to treat, so new therapeutic options are needed. Arvinas is a biopharmaceutical company developing therapies that degrade disease-causing proteins. It developed a platform called PROTAC, which can target any protein for degradation by the body's natural mechanisms. ARV-471 is an oral investigational therapy that uses PROTAC technology to target the ER for degradation. “ARV-471 is a potent ER degrader that has demonstrated significant anti-tumor activity in preclinical models, and we are hopeful it will address an important need for patients with advanced ER-positive breast cancer not adequately treated with current standards of care,” Ronald Peck MD, chief medical officer of Arvinas, said in a news release. The ongoing Phase 1 trial (NCT04072952) will evaluate the effects of ARV-471 for the first time in humans. The study, which is still recruiting participants, plans to enroll 36 people with locally-advanced or metastatic ER-positive, HER2-negative breast cancer. To be eligible, patients must have received at least two prior hormone therapies
Subscribe or to access all post and page content.